Position in ALKS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$251,153
+$37,514 QoQ
Shares Held
4,793
-25.9% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#297
of 421 holders
Holding Since
Dec 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026SHELTON CAPITAL MANAGEMENT holds $2,556,716 across 7 Drug Manufacturers - Specialty & Generic names. ALKS ranks #4 (9.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
1,394 | $755,311 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
3,229 | $544,215 | |
| 3 | ELAN |
Elanco Animal Health Inc
|
16,383 | $403,185 | |
| 4 | ALKS |
Alkermes plc.
This page
|
4,793 | $251,153 | |
| 5 | LNTH |
Lantheus Holdings, Inc.
|
2,186 | $242,514 | |
| 6 | HIMS |
Hims & Hers Health, Inc.
|
6,782 | $235,131 | |
| 7 | BHC |
Bausch Health Companies Inc.
|
25,397 | $125,207 |
All Filings in ALKS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $251,153 | 4,793 | Shares | Sole | 2026-08-14 | |
| 2025-03-31 | $213,639 | 6,470 | Shares | Sole | 2025-05-15 | |
| 2024-09-30 | $214,571 | 7,666 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $203,566 | 7,520 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $224,166 | 8,081 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||